63
Participants
Start Date
October 31, 2005
Primary Completion Date
January 31, 2008
MLN8054
MLN8054 will be administered orally in multiple divided daily doses for 7 days to 21 consecutive days. A 14-day recovery period will follow each dosing period, regardless of its duration. MLN8054 will be supplied in capsules of 5 mg or 25 mg with dose strength expressed as the milligrams of active drug (free acid). MLN8054 will be given on an empty stomach. Patients will be instructed to take nothing by mouth except for water and prescribed medications for 2 hours before and 1 hour after each dose.
The Sarah Cannon Research Institute, Nashville
Lead Sponsor
Millennium Pharmaceuticals, Inc.
INDUSTRY